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In investigating the determinants of survival of prostate cancer cohorts, characterization of 
the cohort in terms of competing underlying causes of death would be appropriate. 
Atherosclerotic heart disease, bronchitis, acute myocardial infarction, chronic obstructive 
pulmonary disease, atherosclerotic cardiovascular disease, and stroke were found to be the 
major causes of death among prostate cancer cohorts aside from prostate cancer. A 
population-based assessment of the codeterminants of mortality and a demographic and 
clinical determinant of prostate cancer survival was undertaken. Average survival time and 
survival curves of the various age categories were significantly different. The average 
survival time and survival curves of the different levels of grade and SEER summary stage 
were significantly different. On average, the regression coefficients of age categories, the 
different levels of grade, and SEER summary stages were significant predictors of survival 
for the prostate cancer cohorts studied. Clinical management of prostate cancer patients 
should consider the risk factors for the identified codeterminants of mortality among prostate 
cancer cohorts. 
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Introduction	  
Prostate cancer is the most commonly diagnosed type of cancer among populations in the United 
States and is estimated to occur at 156.9 per 100,000 men (Centers for Disease Control and 
Prevention, 2010). The mean prostate-cancer-related death rate among all races/ethnicities in the 
United States from 2002 to 2006 is 25.6 per 100,000 persons (Edwards et al., 2010). The total 
healthcare budget associated with prostate cancer from 1998 to 2003 was estimated to vary from 
$2.6 to $4.3 billion (DeVol & Bedroussian, 2007). The mean prostate cancer incidence rate among 
men in Arizona between 1995 and 2007 varied between 112 and 137 per 100,000 persons (Indicator 
Based Information System [IBIS], 2010).  IBIS is a system that allows the public to query cancer 
incidence and mortality estimated in Arizona by year. This public health data access tool is intended 
to support evidenced-based public health decision-making in the state of Arizona. The average 
prostate cancer mortality rate from 2000 to 2007 among men in Arizona varied from 8.32 to 11.52 
per 100,000 persons (IBIS, 2010). The average prostate cancer mortality rate in Arizona is 
consistently lower than that of the U.S. rate (Stoll, 2000); however, assessments of the determinants 
of prostate cancer survival in Arizona are lacking.  
Along with the age of the patient, the stage of prostate cancer at diagnosis and grade are 
hypothesized to determine survival in patients diagnosed with prostate cancer (Stattin et al., 2010). 
This is probably due to the influences of stage and grade on the choice of treatment options or due to 
the associated adverse effects of the kinds of therapeutic measures used (Lepor, 2002); moreover, 
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cardiovascular and other chronic diseases are associated with significant mortality among 
individuals diagnosed with prostate cancer (Ketchandji, Kuo, Shahinian, & Goodwin, 2009). This 
study was conducted with the objective of assessing the demographic and clinical determinants of 
prostate cancer survival and the impact of associated comorbidities associated with cardiovascular 
and other chronic diseases among prostate cancer subjects in the state of Arizona. 
Materials	  and	  Methods	  
This study used population-based prostate cancer surveillance data in Arizona to investigate the 
effects of age at diagnosis, cancer stage, and grade on survival. Other causes of mortality among the 
population of subjects diagnosed with prostate cancer from 1995 to 2007 in the state of Arizona were 
also examined.  Prostate cancer cases were identified from the Arizona Cancer Registry for the years 
1995–2007. The Arizona Cancer Registry is a population-based surveillance system that collects, 
manages, and analyzes information on the incidence and mortality due to cancer, including prostate 
cancer. Cancer cases are abstracted by skilled abstractors at the hospital and then reported to the 
Central Registry, whereby the Registry staff undertakes the task of processing and quality-
controlling the data. Hospitals with fewer than 50 beds are not required to abstract their own cancer 
cases; instead, Central Registry staff travel to those facilities to complete the abstracts. Age, sex, 
race/ethnicity, date of diagnosis, survival time, vital status, stage, and grade at diagnosis are some of 
the important demographic and clinical data that can be identified from the Registry database for 
each subject. 
From 1995 to 2007, a total of 35,528 prostate cancer cases were identified from the Registry using 
The International Classification of Diseases for Oncology, ICD-O-2 (Percy, Van Holten, & Muir, 
1990) and ICD-O-3 (Fritz et al., 2000).  The underlying causes of death were identified using The 
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM; World Health 
Organization, 1992) and International Statistical Classification of Diseases and Related Health 
Problems, 10th Revision, (ICD-10; World Health Organization, 1999) codes for prostate cancer. Of 
these cases, other competing underlying causes of death were identified and their percentage 
contributions were described. Subjects who died of other causes of death were excluded from 
analysis. This resulted in total of 27,831 prostate cancer cases that were used for assessing survival. 
Descriptive statistics of age were generated for characterizing the cohort in terms of age groups. To 
examine the effect of age on survival, age groups were categorized. Mortality due to the comorbidities 
of cardiovascular and other chronic diseases among the cohorts was examined. 
Surveillance, Epidemiology and End Results (SEER) staging (0, 1, 2, 3, 4, and 7; Beahrs, Henson, 
Hutter, & Kennedy, 1992) was used in characterizing and describing the effect of prostate cancer 
staging on survival time. The prostate cancer histological grading system of Beahrs et al. (1992) was 
used in describing the effect of grading on survival. Kaplan-Meier survival curves were used to 
compare survival time among the various categories of age and levels of stage and grade using IBM 
SPSS Statistics 19. Cox proportional hazards regression was used to investigate the predictive 
significance of age, grade, and stage on survival. The backward stepwise (likelihood ratio) method 
was used in fitting the Cox proportional hazards model. The hypothesis tested was that age, grade, 
and SEER summary stage are not significant predictors of survival. 
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Results	  
The proportions of nonprostate cancer related mortality are presented in Figure 1. After prostate 
cancer, the major causes of death among the cohort include atherosclerosic heart disease, bronchitis, 
acute myocardial infarction, chronic obstructive pulmonary disease, atherosclerotic cardiovascular 
disease, and stroke.  
 
Figure	  1.	  Major	  Causes	  of	  Mortality	  in	  the	  Cohort	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The age distribution among the cohort by vital status in which all causes of mortality were 
considered is shown in Figure 2; the distribution in which only mortality due to prostate cancer was 
considered is shown in Figure 3. The average age among the cohorts in which all causes of mortality 
were considered was 66 for those who were alive and 73 for those who were deceased (Figure 2).  
	  
Figure	  2.	  The	  Distribution	  of	  Age	  Among	  the	  Cohort	  by	  Vital	  Status	  in	  Which	  Other	  Underlying	  
Causes	  of	  Death	  Are	  Included	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The average age among the cohorts in which only mortality due to prostate cancer was considered 
was 66 for those who were alive and 72 for those who were deceased (Figure 3). This analysis 
indicated that the average age distribution is very similar when other underlying causes of death are 
considered aside from prostate cancer.  
 
Figure	  3.	  The	  Distribution	  of	  Age	  Among	  the	  Cohort	  by	  Vital	  Status	  in	  Which	  Only	  Mortality	  Due	  
to	  Prostate	  Cancer	  Cases	  Were	  Considered	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Comparisons of average survival time among the various categories of age, levels of grade, and SEER 
summary stage are given in Figures 4, 5, and 6, respectively. The log-rank test indicated that the 
average survival time is significantly different between the various age categories. The average 
survival time was shortest for the age group 81 and above, followed by the youngest age group (31–
40; Figure 4).  
 
Figure	  4.	  Average	  Survival	  Time	  as	  Function	  of	  Age	  Group	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Similarly, the log-rank test showed that the average survival times of the various grades were 
significantly different from each other. The relationship between average survival time and grade 
was an inverse linear relationship. The lower the prostate cancer grade, the longer was the average 
survival time (Figure 5).  
 
Figure	  5.	  Average	  Survival	  Time	  as	  Function	  of	  Grade	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Based on the log-rank test, the various stages had significantly different mean survival times. A 
similar trend was observed with regards to the association between the SEER summary stage and 
average survival time, although the average survival time for the SEER summary stage 0 was less 
than that of stage 1 (Figure 6). In particular, the average survival time for the highest SEER 




Figure	  6.	  Average	  Survival	  Time	  as	  Function	  of	  SEER	  Summary	  Stage	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Survival curves for the various categories of age, levels of grade, and SEER summary stages are 
presented in Figures 7, 8, and 9, respectively. Figure 7 shows that age group 81 and above has the 
lowest cumulative survival rate, followed by the age category 71–80. Age groups 41–50 and 51–60 
have a very similar cumulative survival curve.  
 
Figure	  7.	  Survival	  Curves	  for	  the	  Various	  Age	  Groups	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Figure 8 corroborates what is presented in Figure 5 in terms of average survival time. The 
cumulative survival rate for grade level 4 is the lowest among all grade levels described in the 
cohort. While the survival curves of grade levels 1 and 2 were very closely related, the survival 
curves for grades 4 and 5 were very similar.  
 
Figure	  8.	  Survival	  Curves	  for	  the	  Various	  Grades	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The cumulative survival rate for SEER summary stage 7 was the lowest among all stages described, 
while SEER summary stage 1 had the highest cumulative survival rate (Figure 9).  This agrees with 
the result presented in Figure 5 regarding the distribution of average survival time for the various 
SEER summary stages.  
  
Figure	  9.	  Survival	  Curves	  for	  the	  Various	  SEER	  Summary	  Stages	  
Table 1 presents the measures for overall model fitness (omnibus tests of model coefficients).   
Table	  1.	  Omnibus	  Tests	  of	  Model	  Coefficients	  
Overall  
(Score) 
Change From  
Previous Step 





Square df Sig. 
Chi-
Square df Sig. 
Chi-
Square df Sig. 
22,744.048 9,407.485 13 .000 3,122.207 13 .000 3,122.207 13 .000 
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The overall mode fit is significant. Regression coefficients for the various variables and levels of 
variables included in the Cox regression model for predicting survival are presented in Table 2. 
Results presented in Table 2 show that on average, grade, stage, and age are significant predictors of 
survival, although grade 3 and SEER summary stages 0 and 1 were not significant predictors of 
survival compared to their respective reference groups. 
Table	  2.	  Regression	  Coefficients	  for	  the	  Various	  Levels	  of	  the	  Variables	  Included	  in	  the	  	  
Cox	  Regression	  Coefficients	  
95.0% CI for 
Exp(B) 
Variable B SE Wald df Sig. Exp(B) Lower Upper 
Grade     332.48 3 .000       
1 -1.5 .203 53.41 1 .000 .23 .15 .34 
2 -1.2 .154 63.34 1 .000 .29 .22 .40 
3 -.2 .149 1.77 1 .183 .82 .61 1.10 
Age Group      782.96 5 .000       
1 -1.6 .710 4.85 1 .028 .21 .05 .84 
2 -2.3 .201 129.87 1 .000 .10 .07 .15 
3 -2.4 .108 476.51 1 .000 .10 .08 .12 
4 -2.1 .084 617.49 1 .000 .12 .10 .15 
5 -1.2 .078 223.67 1 .000 .31 .27 .36 
SEER Summary Stage      1829.95 5 .000       
1 -.3 .556 .34 1 .561 .72 .24 2.15 
2 .4 .287 2.11 1 .147 1.52 .86 2.67 
3 1.1 .253 20.59 1 .000 3.16 1.92 5.19 
4 .7 .244 8.62 1 .003 2.04 1.27 3.30 
5 2.1 .134 244.54 1 .000 8.18 6.29 10.64 
Note: Wald = the Wald test (a test statistic used for testing whether the parameters associated with a group of 
explanatory variables are zero); Exp(B) = used to exponentiate the coefficients of the predictor variables 
included in the model to get a hazard ratio for a unit increase in the predictor variable. 
Discussion	  
An elevated risk of cardiac and pulmonary dysfunction is observed among prostate cancer patients 
(Carver et al., 2007; Ketchandji et al., 2009). In the prostate cancer cohorts assessed in the current 
study, atherosclerotic heart disease was the second most important cause of death next to prostate 
cancer. Increased risk of death due to heart diseases among prostate cancer patients is attributed 
primarily to the impacts of prostate cancer therapy types, such as hormonal treatment (Tsai, 
D'Amico, Sadetsky, Chen, & Carroll, 2007). Hormonal treatment of prostate cancer is hypothesized 
to lead to pulmonary complications (Seigneur, Trechot, Hubert, & Lamy, 1988). On the other hand, 
the proportion of patients who died of atherosclerotic heart disease after using hormonal therapy 
was about 18%. The risk of treatment-related side effects in treating prostate cancer is likely related 
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to the stage of prostate cancer (metastatic versus nonmetastatic). Hormonal therapy is the primary 
treatment modality for patients with metastatic prostate cancer. Prostate cancer tumors are 
metastasized to the lungs and bones through the blood stream or the lymphatic system (Rusch, 
2008). 
Most of the chronic diseases identified as the major causes of death in the cohort have overlapping 
risk factors, and one health ailment is a risk factor for another. In this regard, chronic obstructive 
pulmonary disease is recognized as a risk factor for cardiovascular mortality among patients with 
ischemic heart disease (Nishiyama et al., 2010). The important risk factors for atherosclerotic heart 
disease are obesity, smoking, hypertension, high cholesterol, and type 2 diabetes (Saeed et al., 2009). 
In the current study, stroke was observed to be one of the underlying causes of death among the 
prostate cancer cohorts. This is probably due to the endocrine treatment effect of prostate cancer, in 
which it is found to increase the risk of stroke and ischemic heart disease (Robinson et al., 2011). 
Most of these risk factors are modifiable risk factors and need to be considered in the clinical 
management of prostate cancer patients.  
Age is an important demographic determinant of prostate cancer survival, mainly because it affects 
the risk of prostate cancer and choice of therapeutic options. Bechis, Carroll, and Cooperberg (2010) 
found that patients diagnosed with advanced stages of prostate cancer have elevated risks of death 
because they have a lower chance of receiving local therapy, which negatively affects their survival. 
As observed among these cohorts, however, the youngest subjects could have low cumulative survival 
rate. Lin, Porter, and Montgomery (2009) found that younger men who have high-grade and 
advanced stages of prostate cancer could have a lower survival rate than older subjects. The 
etiological processes and factors that lead to lower survival rates among younger subjects warrant 
further investigation. 
The effects of cancer stage and grade at time of diagnosis on prostate cancer survival have been well 
documented (Ketchandji et al., 2009). While older men with early stages of prostate cancer have a 
similar survival rate to those without prostate cancer (Keating, O'Malley, & Smith, 2006), younger 
men with high-grade and advanced stages of prostate cancer have a lower survival rate (Lin et al., 
2009). Advanced stages and grades of prostate cancer are typically associated with lower survival 
rates because these clinical characteristics of prostate cancer are likely indicators of metastasized 
phases of that disease (Saad, 2009). Prostate cancer is known to metastasize preferentially to bone 
(Logothetis and Lin, 2005). Metastasized prostate cancer can lead to a significant increase in 
morbidity, owning to nerve compression that is likely caused by pathological fractures associated 
with the metastasis of the cancer; moreover, it increases the heath care cost (Lage, Barber, Harrison, 
& Jun, 2008) in addition to increasing morbidity, which eventually reduces survival.  
Although population-based, this study has a number of limitations because it relied on registry data. 
Based on results from cancer-registry-based data analyses, it is very difficult to know whether longer 
survival is due to early diagnosis or more effective treatment modalities (Berrino, 2003). Case 
underreporting is also one of the limitations of registry-based studies. The Arizona Cancer Registry 
precludes cancer cases reported solely based on death certificate. This is typically due to the fact that 
death certificates do not indicate the date of diagnosis (Bullard et al., 2000). 
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  behavioral,	  and	  
health	  sciences	  that	  address	  complex	  social	  problems;	  and	  (c)	  inform	  the	  relationship	  between	  
practice	  and	  research	  in	  the	  social,	  behavioral,	  and	  health	  sciences.	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